248 related articles for article (PubMed ID: 34188973)
1. Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers.
Tata A; Dodard G; Fugère C; Leget C; Ors M; Rossi B; Vivier E; Brossay L
Oncoimmunology; 2021 Jun; 10(1):1933808. PubMed ID: 34188973
[TBL] [Abstract][Full Text] [Related]
2. The role of KLRG1: a novel biomarker and new therapeutic target.
Zhang Y; Chen S; Tang X; Peng Y; Jiang T; Zhang X; Li J; Liu Y; Yang Z
Cell Commun Signal; 2024 Jun; 22(1):337. PubMed ID: 38898461
[TBL] [Abstract][Full Text] [Related]
3. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
4. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
5. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
8. Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.
Battaglia NG; Murphy JD; Uccello TP; Hughson A; Gavras NW; Caldon JJ; Gerber SA; Lord EM
J Immunol; 2022 Aug; 209(3):629-640. PubMed ID: 35840162
[TBL] [Abstract][Full Text] [Related]
9. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.
Boer MC; van Meijgaarden KE; Goletti D; Vanini V; Prins C; Ottenhoff TH; Joosten SA
Tuberculosis (Edinb); 2016 Mar; 97():163-71. PubMed ID: 26750180
[TBL] [Abstract][Full Text] [Related]
10. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
11. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
12. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
13. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
14. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Shirinbak S; Chan RY; Shahani S; Muthugounder S; Kennedy R; Hung LT; Fernandez GE; Hadjidaniel MD; Moghimi B; Sheard MA; Epstein AL; Fabbri M; Shimada H; Asgharzadeh S
Oncoimmunology; 2021 Jan; 10(1):1838140. PubMed ID: 33489468
[TBL] [Abstract][Full Text] [Related]
15. Expression of inhibitory "killer cell lectin-like receptor G1" identifies unique subpopulations of effector and memory CD8 T cells.
Beyersdorf NB; Ding X; Karp K; Hanke T
Eur J Immunol; 2001 Dec; 31(12):3443-52. PubMed ID: 11745363
[TBL] [Abstract][Full Text] [Related]
16. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
17. KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.
Assatova B; Willim R; Trevisani C; Haskett G; Kariya KM; Chopra K; Park SR; Tolstorukov MY; McCabe SM; Duffy J; Louissaint A; Huuhtanen J; Bhattacharya D; Mustjoki S; Koh MJ; Powers F; Morgan EA; Yang L; Pinckney B; Cotton MJ; Crabbe A; Ziemba JB; Brain I; Heavican-Foral TB; Iqbal J; Nemec R; Rider AB; Ford JG; Koh MJ; Scanlan N; Feith DJ; Loughran TP; Kim WS; Choi J; Roels J; Boehme L; Putteman T; Taghon T; Barnes JA; Johnson PC; Jacobsen ED; Greenberg SA; Weinstock DM; Jain S
Clin Cancer Res; 2024 Jun; 30(11):2514-2530. PubMed ID: 38252421
[TBL] [Abstract][Full Text] [Related]
18. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
